Horizon Two

Horizon Two: HR NDMM (MMRC-100)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
300 patients (estimated)
Tags
T Cell Engager (TCE), Bispecific Antibody, B-Cell Maturation Antigen (BCMA), Randomization, High Risk, Maintenance
Trial Type
Treatment
Last Update
SparkCures ID
2254
NCT Identifier
NCT07053436

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.